Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin And Glp-1 Programs For Chronic Weight Management
GPCR•Positive clinical data across weight management programs
Sept. 8 (Reuters) - Structure Therapeutics Inc. GPCR.O:
- Structure Therapeutics reports positive clinical data across oral small molecule amylin and GLP-1 programs for chronic weight management
- Structure Therapeutics - additional clinical data for aleniglipron expected in Q4 2026
- Structure Therapeutics - ACCG-2671 demonstrates about 6-day half-life, no serious adverse events, 3.3% body weight loss in Phase 1/2a SAD trial
- Structure Therapeutics - first participants dosed with ACCG-2671 in 12-week MAD Phase 1/2a trial; topline data expected 1H 2027
- Structure Therapeutics - aleniglipron demonstrates up to 16.2% body weight reduction at 72 weeks in ACCESS OLE trial
